国际老年肿瘤学会关于老年转移性肾细胞癌患者的立场文件
国际老年肿瘤学会(SIOG)工作组更新了2009年关于老年转移性肾细胞癌管理的共识声明,回顾了近期获批靶向药物和免疫治疗的研究数据。总体而言,年龄本身似乎不显著影响疗效,但关键研究中将毒性反应与患者年龄相关联的分析非常缺乏。即使老年患者的不良反应频率或严重程度与年轻患者相当,治疗的实际、心理和功能影响可能更大,尤其是当毒性反应为慢性和累积性时。
要点
- 年龄不应成为有效治疗的障碍,治疗应个体化。
- 系统老年筛查和评估有助于个性化管理。
- 需关注治疗对老年患者功能和生活质量的影响。
核心结论
- 年龄本身似乎不显著影响转移性肾细胞癌治疗的疗效。
- 老年患者治疗的实际、心理和功能影响可能更大,尤其毒性为慢性和累积性时。
研究设计与样本
- SIOG工作组更新2009年共识声明,回顾近期获批靶向药物和免疫治疗的研究数据。
主要发现
- 关键研究中将毒性反应与患者年龄相关联的分析非常缺乏。
- 即使老年患者不良反应频率或严重程度与年轻患者相当,治疗影响可能更大。
临床怎么用
- 治疗应个体化,结合患者情况和偏好,年龄不应成为治疗障碍。
- 进行系统老年筛查和评估,并涉及多学科团队。
局限性
- 关键研究中缺乏毒性反应与年龄关系的分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy for metastatic renal cell carcinoma should be tailored to the circumstances and preferences of the individual patient. Age should not be a barrier to effective treatment. Systematic geriatric screening and assessment contributes to the goal of personalised management, in addition to the involvement of a multidisciplinary team. A task force from the International Society of Geriatric Oncology (SIOG) updated its 2009 consensus statement on the management of elderly patients with metastatic renal cell carcinoma by reviewing data from studies involving recently approved targeted drugs and immunotherapies for this disease. Overall, it seems that age alone does not appreciably affect efficacy. Among the pivotal studies that were included, there is a striking scarcity of analyses that relate toxic effects to patient age. Even if the adverse effects of therapy are no more frequent or severe in elderly patients than in their younger counterparts, the practical, psychological, and functional impact of treatment may be greater, especially if toxic effects are chronic and cumulative.
引用
- Kanesvaran R, Le Saux O, Motzer R, et al. Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018. PMID: 29893263. doi:10.1016/S1470-2045(18)30125-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。